Bolivia Medical Device Tecnovigilancia and Adverse Incident Reporting: AGEMED Compliance Guide

1. Key takeaways

Technovigilance for medical devices in Bolivia is coordinated by the surveillance and control department of AGEMED and sits, together with pharmacovigilance, within the national vigilance system. The institutional foundation comes from Article 2 of Ley N° 1737 of 17 December 1996, which brings medical devices within the scope of that law. On the operational side, the link to the manufacturer is established when the manufacturer representative document is filed with the surveillance and control department, as provided in Section 2.3.4 of the Manual. The GRZAN assessment is straightforward: the responsible party on paper is the license holder, while the origin of safety information is the manufacturer, and the interface between the two must be written into the distribution agreement. If that interface is left to informal practice, the vigilance chain breaks at its most critical link, precisely when an adverse incident demands a fast and documented exchange between the field, the importer, and the manufacturer abroad.

The practical division of labor follows the structure of the system. The license holder is the entity AGEMED can reach, sanction, and document, because it holds the sanitary registration and filed the representative document. The manufacturer holds the design records, the risk management file, and the production data needed to judge whether an event reflects an isolated failure or a systemic defect. Neither side can discharge the obligation alone: the license holder cannot investigate a defect it cannot see into, and the manufacturer cannot report through a channel it does not formally occupy. GRZAN therefore treats the distribution agreement not as a commercial document but as the load-bearing element of the vigilance architecture, and reviews it accordingly before any first shipment to Bolivia.

2. Legal basis

3. Expert insights

Insight one: the representative document is filed with the surveillance and control department, and that placement is not accidental. Section 2.3.4 routes the manufacturer representative document to the same unit that runs technovigilance. This fixes the technovigilance contact path at the registration stage, years before any incident may occur. Companies should make sure the contact named in the filed document is a technical function capable of receiving and processing vigilance information, not merely a commercial contact. A named salesperson who cannot interpret an incident report, request batch documentation, or coordinate a field corrective action will slow the response exactly when timelines matter, and the deficiency will be visible in the file that AGEMED already holds.

Insight two: the installation report for biomedical equipment is the infrastructure of vigilance. Section 2.9 requires the license holder to report, year by year, the quantity and location of installed equipment. Once this distribution inventory exists, AGEMED can locate affected devices when a vigilance event arises. Companies should treat it as a precondition for recall and field corrective action capability, not merely as an annual reporting chore. A maintained distribution ledger converts a vague obligation into a working tool: when a defect is suspected, the affected population can be enumerated by site and serial range within hours, and the scope of any correction can be justified with data rather than assumptions. The ledger should also record installation dates and service history where equipment is maintained locally, because those fields are the first questions an investigator asks when a failure pattern emerges across sites.

Insight three: vigilance records, re-registration, and inspection share one information pool. Vigilance history is consulted during re-registration review and referenced during on-site inspections. A single unresolved incident can resurface five years later at the re-registration stage, under the practical estimate used by GRZAN in project work. Keeping incident files complete, closed out, and retrievable is therefore not only a vigilance duty but an asset for the next registration cycle. In file reviews, GRZAN has observed that a company able to show closed incident files with documented outcomes presents a materially better compliance profile than one presenting an empty file with no history, because the empty file raises the question of whether events were captured at all rather than whether none occurred.

4. Practical recommendations

1. Write the vigilance information interface into the distribution agreement: state how quickly the manufacturer must notify the license holder of adverse information arising abroad, and how quickly the license holder must submit the corresponding report to AGEMED, so that both clocks are contractual rather than discretionary.
2. Ensure the filed contact person is a technical role, empowered to handle incident reports, coordinate investigations with the manufacturer, and communicate with AGEMED without routing every message through commercial staff.
3. Build the annual installation report as a living device distribution ledger, updated at every shipment and installation, and reuse it as the factual basis for recall exercises, complaint trending, and the annual review of the license.

A short worked example shows the value of the setup. Suppose a hospital reports that an infusion device stopped mid-session. With the interface in place, the importer notifies the license holder the same day, the license holder reaches the technical contact, and the manufacturer receives the event log and batch data within the contractual window. The distribution ledger identifies every unit of the affected batch and the sites where it is installed. The report to the surveillance and control department goes out through the channel fixed at registration, and the file closes with a documented outcome. Remove any one of those elements and the same event becomes a week of phone calls, an incomplete record, and an authority that learns about the incident from the hospital instead of from the company.

5. Verification checklist

• □ Is the contact person named in the filed manufacturer representative document a technical function?
• □ Does the distribution agreement state two-way notification time limits for vigilance information?
• □ Has a device distribution ledger been established, consistent with the annual report under Section 2.9?
• □ Is there a demonstrated ability to trace by batch and execute field corrective action?
• □ Are vigilance records archived and retrievable for re-registration?

Regulatory information verified as of October 29, 2026.

GRZAN supports medical device manufacturers, importers, and authorized representatives with sanitary registration, technovigilance setup, and post-market compliance in Bolivia. For assistance with this topic, contact info@grzanglobal.com.